[go: up one dir, main page]

BR9712782A - Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf) - Google Patents

Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf)

Info

Publication number
BR9712782A
BR9712782A BR9712782-5A BR9712782A BR9712782A BR 9712782 A BR9712782 A BR 9712782A BR 9712782 A BR9712782 A BR 9712782A BR 9712782 A BR9712782 A BR 9712782A
Authority
BR
Brazil
Prior art keywords
pde
tnf
necrosis factor
tumor necrosis
inhibitors
Prior art date
Application number
BR9712782-5A
Other languages
English (en)
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of BR9712782A publication Critical patent/BR9712782A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Patente de Invenção:<B>"DERIVADOS DE INDAZOL SUBSTITUìDO E SEU USO COMO INIBIDORES DE FOSFODIESTEROSE (PDE) E FATOR DE NECROSE DE TUMOR (TNF)"<D>. A invenção diz respeito a compostos da fórmula I e seus sais farmaceuticamente aceitáveis, em que R, R~ 1~ e R~ 2~ são conforme aqui definidos. A invenção diz ainda respeito a composições farmacêuticas que os contêm e a métodos de utilização dos compostos de fórmula I, ou seus sais aceitáveis, para inibição de fosfodiesterase (PDE) tipo IV ou da produção de fator de necrose de tumor (TNF) num mamífero.
BR9712782-5A 1996-06-25 1997-06-02 Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf) BR9712782A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2038596P 1996-06-25 1996-06-25
PCT/IB1997/000630 WO1997049702A1 (en) 1996-06-25 1997-06-02 Substituted indazole derivatives and their use as phosphodiesterase (pde) type iv and tumor necrosis factor (tnf) inhibitors

Publications (1)

Publication Number Publication Date
BR9712782A true BR9712782A (pt) 1999-12-07

Family

ID=21798354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712782-5A BR9712782A (pt) 1996-06-25 1997-06-02 Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf)

Country Status (42)

Country Link
US (1) US6040329A (pt)
EP (1) EP0912558B1 (pt)
JP (1) JP3152940B2 (pt)
KR (1) KR20000022516A (pt)
CN (1) CN1080260C (pt)
AP (1) AP1025A (pt)
AR (1) AR007456A1 (pt)
AT (1) ATE244713T1 (pt)
AU (1) AU716376B2 (pt)
BG (1) BG64052B1 (pt)
BR (1) BR9712782A (pt)
CA (1) CA2258285C (pt)
CO (1) CO4900056A1 (pt)
CZ (1) CZ423398A3 (pt)
DE (1) DE69723447T2 (pt)
DK (1) DK0912558T3 (pt)
DZ (1) DZ2254A1 (pt)
EA (1) EA002274B1 (pt)
ES (1) ES2201299T3 (pt)
GT (1) GT199700075A (pt)
HN (1) HN1997000079A (pt)
HR (1) HRP970350B1 (pt)
HU (1) HUP9903009A3 (pt)
ID (1) ID18579A (pt)
IL (1) IL127036A (pt)
IS (1) IS4910A (pt)
MA (1) MA24225A1 (pt)
MY (1) MY116915A (pt)
NO (1) NO986103L (pt)
NZ (1) NZ332752A (pt)
OA (1) OA10934A (pt)
PA (1) PA8432301A1 (pt)
PL (1) PL330974A1 (pt)
PT (1) PT912558E (pt)
SI (1) SI0912558T1 (pt)
SK (1) SK176598A3 (pt)
TN (1) TNSN97108A1 (pt)
TR (1) TR199802685T2 (pt)
TW (1) TW434237B (pt)
WO (1) WO1997049702A1 (pt)
YU (1) YU60198A (pt)
ZA (1) ZA975581B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
PL332187A1 (en) * 1996-09-04 1999-08-30 Pfizer Substitution derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and tumor necrosis factor (tnf)
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
CA2309175A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
HUP0004150A3 (en) * 1997-11-04 2001-08-28 Pfizer Prod Inc Indazole derivatives as tyrosine kinase receptor antagonists and pharmaceutical compositions containing them
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
US7153871B2 (en) 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US7205320B2 (en) 2001-01-22 2007-04-17 Memory Pharmaceuticals Corp. Phosphodiesterase 4 inhibitors
CA2440842A1 (en) * 2001-04-16 2002-10-24 Eisai Co., Ltd. Novel 1h-indazole compounds
KR20040075004A (ko) 2001-12-14 2004-08-26 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 비폴리펩티드 고리에이엠피 레벨 모듈레이터를 이용한배란 유도 방법
BR0313000A (pt) * 2002-07-19 2005-07-12 Memory Pharm Corp Compostos, composição farmacêutica e método para efetuar a inibição da enzima pde4, realçar a cognição e/ou tratar a psicose em um paciente
EP1539697A1 (en) 2002-07-19 2005-06-15 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
CN100513397C (zh) * 2002-11-19 2009-07-15 记忆药物公司 磷酸二酯酶4抑制剂
US7226930B2 (en) 2003-04-18 2007-06-05 Memory Pharmaceutical Corporation Phosphodiesterase 4 inhibitors
US20090048255A1 (en) * 2003-07-21 2009-02-19 Schumacher Richard A Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
MY141255A (en) * 2003-12-11 2010-03-31 Memory Pharm Corp Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EP1799673A1 (en) * 2004-10-15 2007-06-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
WO2006129158A2 (en) * 2005-05-30 2006-12-07 Ranbaxy Laboratories Limited 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1928866A1 (en) * 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
ATE545417T1 (de) 2007-03-14 2012-03-15 Ranbaxy Lab Ltd Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
NZ599597A (en) * 2009-10-30 2013-05-31 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
KR20220167441A (ko) * 2021-06-11 2022-12-21 주식회사 메타센테라퓨틱스 신규한 인돌 유도체 및 이의 최종당화산물 관련 질환의 치료 용도
KR20220167804A (ko) * 2021-06-11 2022-12-22 주식회사 메타센테라퓨틱스 인돌 유도체를 포함하는 최종당화산물 관련 질환의 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB753573A (en) * 1953-06-17 1956-07-25 Ici Ltd New dyestuffs intermediates
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
PT100441A (pt) * 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
TW223004B (pt) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
SK279958B6 (sk) * 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
JPH07215952A (ja) * 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
WO1996012720A1 (en) * 1994-10-20 1996-05-02 Pfizer Inc. Bicyclic tetrahydro pyrazolopyridines and their use as medicaments

Also Published As

Publication number Publication date
AP9701020A0 (en) 1997-07-31
HUP9903009A2 (hu) 2000-05-28
EP0912558A1 (en) 1999-05-06
MY116915A (en) 2004-04-30
PL330974A1 (en) 1999-06-21
KR20000022516A (ko) 2000-04-25
CO4900056A1 (es) 2000-03-27
HUP9903009A3 (en) 2002-01-28
IS4910A (is) 1998-11-27
BG64052B1 (bg) 2003-11-28
DE69723447T2 (de) 2003-12-24
BG103056A (en) 1999-10-29
ZA975581B (en) 1998-12-24
WO1997049702A1 (en) 1997-12-31
JP3152940B2 (ja) 2001-04-03
CZ423398A3 (cs) 1999-12-15
TW434237B (en) 2001-05-16
US6040329A (en) 2000-03-21
NO986103D0 (no) 1998-12-23
HN1997000079A (es) 1997-12-26
NZ332752A (en) 2001-04-27
NO986103L (no) 1998-12-23
SI0912558T1 (en) 2003-10-31
IL127036A (en) 2001-06-14
EA002274B1 (ru) 2002-02-28
IL127036A0 (en) 1999-09-22
ATE244713T1 (de) 2003-07-15
MA24225A1 (fr) 1997-12-31
AR007456A1 (es) 1999-10-27
PA8432301A1 (es) 1999-12-27
DK0912558T3 (da) 2003-08-18
TNSN97108A1 (fr) 2005-03-15
DE69723447D1 (de) 2003-08-14
CA2258285A1 (en) 1997-12-31
CA2258285C (en) 2002-11-26
AP1025A (en) 2001-11-19
CN1223651A (zh) 1999-07-21
EA199801047A1 (ru) 1999-06-24
PT912558E (pt) 2003-11-28
AU2785797A (en) 1998-01-14
GT199700075A (es) 1998-12-04
ES2201299T3 (es) 2004-03-16
CN1080260C (zh) 2002-03-06
TR199802685T2 (xx) 1999-03-22
AU716376B2 (en) 2000-02-24
OA10934A (en) 2002-02-18
HK1018700A1 (en) 1999-12-30
JPH11514668A (ja) 1999-12-14
SK176598A3 (en) 2000-06-12
EP0912558B1 (en) 2003-07-09
ID18579A (id) 1998-04-23
HRP970350B1 (en) 2003-04-30
HRP970350A2 (en) 1998-06-30
DZ2254A1 (fr) 2002-12-18
YU60198A (sh) 1999-09-27

Similar Documents

Publication Publication Date Title
BR9712782A (pt) Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf)
NO991048L (no) Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)
MY132499A (en) Substituted indazole derivatives and related compounds
EP1079826B1 (en) Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases
BR9906013A (pt) Derivados bicìclicos heteroaromáticos úteis como agentes anticancerìgenos
FI951454A0 (fi) 1-(2-oksoasetyyli)piperidiini-2-karboksyylihappojohdannaiset monille lääkkeille resistenttien syöpäsolujen herkistäjinä
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
BRPI0518651A2 (pt) composto, uma prà-droga do mesmo, ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, composiÇço farmacÊutica, inibidor de dipeptidil peptidase iv, uso de um composto, uma prà-droga do mesmo ou um sal do composto ou prà-droga farmaceuticamente aceitÁvel, e, mÉtodo para tratar diabetes
BRPI0313942B8 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
NO331166B1 (no) Inhibitorer av tyrosinkinaser, fremgangsmate for fremstilling derav, farmasoytisk preparat samt anvendelse av forbindelsene
BRPI0411863A (pt) derivados de pirazolil-indol como inibidores de cinase, processo para seu preparo e composições farmacêuticas compreendendo os mesmos
MY141220A (en) Pyrazole derivatives as inhibitors of receptor tyrosine kinases
BR0011274A (pt) Derivados tipo indol como inibidores de p38 quinase
BRPI0409991A (pt) derivados de 1-(2h-pirazol-3-il)-3-{4-&#39;1-(benzoil)-piperidin-4-ilmetil-fe nil}-uréia e compostos afins como inibidores da cinase p38 e/ou como inibidores de tnf para o tratamento de inflamações
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
ES2376277T3 (es) Uso del �?cido cafeico y dervados como agentes anticancerosos.
DE69709493D1 (de) Substituierte Indazolderivate
BR0316950A (pt) Derivados de indazol como antagonistas de crf
BRPI9913542B8 (pt) derivados de dihidrobenzodioxina carboxamida e dihidrobenzodioxina cetona como antagonistas do receptor 5-ht4 bem como composição farmacêutica, processo para a preparação dos referidos derivados e uso dos mesmos
ES2157314T3 (es) Derivados triciclicos y su uso en productos farmaceuticos.
MX2023004033A (es) Espiro derivados de alfa-d-galactopiranosidos.
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
PA8622801A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]